Capillary Electrophoresis Genetic Analyzers Introduced for Clinical Use

A new series of electrophoresis genetic analyzers is intended for clinical use. The analyzers will be launched in specific countries within the European Union.

The 3500 Dx A platforms provide state-of-the-art advancements in CE sequencing systems, setting new standards for throughput, data quality, and ease-of-use. These analyzers are intended for use in the analysis of human DNA or RNA for the detection of genetic changes that may lead to disease presence or susceptibility.


The 3500 series (for research only) and 3500 Dx series were introduced by Applied Biosystems (Foster City, CA, USA) a division of Life Technologies Corporation. The new genetic analyzers provide an integrated solution that combines the instrument with Applied Biosystems reagents, consumables, software, service and support. Scientists are using the technology to study the most widely recognized human genetic disorders, such as those caused by extra or missing chromosomes, as well as a broad spectrum of other disorders.

The system and accessories comply with the European Union in vitro diagnostic (IVD) medical devices directive 98/79/EC. Commercial launch of the 3500 Dx series systems is anticipated in August 2009.

Life Technologies Corporation, a global biotechnology tools company, was formed by a merger between Applied Sciences and Invitrogen (Carlsbad, CA, USA) in November 2008.

Related Links:
Applied Biosystems
Life Technogies Corp